These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16334985)

  • 21. The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access.
    Esmail LC; Kohler JC
    Global Health; 2012 Apr; 8():7. PubMed ID: 22472291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reforming Canada's Access to Medicines Regime.
    Esmail LC
    CMAJ; 2007 Jul; 177(3):270. PubMed ID: 17664454
    [No Abstract]   [Full Text] [Related]  

  • 24. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 25. Abbott's AIDS fight-back.
    Check E
    Nature; 2007 Jul; 448(7149):14. PubMed ID: 17611514
    [No Abstract]   [Full Text] [Related]  

  • 26. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 27. Compulsory licensing for bridging the gap - treatment access in developing countries: interview with James Love, Consumer Project on Technology. Interview by John S. James.
    Love J
    AIDS Treat News; 1999 Mar; (No 314):1-7. PubMed ID: 11366241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benchmarking progress in tackling the challenges of intellectual property, and access to medicines in developing countries.
    Musungu SF
    Bull World Health Organ; 2006 May; 84(5):366-70. PubMed ID: 16710545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The performance and problems of the Turkish pharmaceutical industry: is there a need to develop a national drug policy?
    Kisa A
    J Med Syst; 2001 Oct; 25(5):309-18. PubMed ID: 11508904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternatives to the drug research and development model.
    Velásquez G
    Salud Colect; 2015 Mar; 11(1):23-34. PubMed ID: 25853828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Access to essential drugs in developing countries].
    Rojo P
    Gac Sanit; 2001; 15(6):540-5. PubMed ID: 11858791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WTO TRIPS and its effect on the supply and development of medicines in China.
    Tanner JA
    Hong Kong Med J; 2006 Feb; 12(1):84-6. PubMed ID: 16495599
    [No Abstract]   [Full Text] [Related]  

  • 35. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
    Hill JE
    Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 38. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action on Canada's generic drug law.
    Abi-Jaoude E
    CMAJ; 2004 Apr; 170(9):1374; author reply 1374-5. PubMed ID: 15111456
    [No Abstract]   [Full Text] [Related]  

  • 40. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.